The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 24, 2014, Pages

  Iannotti, Fabio A ^a   Silvestri, Cristoforo ^a   Mazzarella, Enrico ^a   Martella, Andrea ^a   Calvigioni, Daniela ^b,c   Piscitelli, Fabiana ^a   Ambrosino, Paolo ^d   Petrosino, Stefania ^a   Czifra, Gabriella ^e   Bíŕo, Tamás ^e   Harkany, Tibor ^b,c   Taglialatela, Maurizio ^d   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Medical University of Vienna   (Austria)

^d UNIVERSITY OF MOLISE   (Italy)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ARACHIDONOYL 2 CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; POTASSIUM CHANNEL KCNQ4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHO CELL LINE; CONTROLLED STUDY; EMBRYO; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; MOUSE; MUSCLE CELL; MUSCLE DEVELOPMENT; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SKELETAL MUSCLE SATELLITE CELL; WILD TYPE;

ANIMALS; ARACHIDONIC ACIDS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCANNABINOIDS; GENE SILENCING; GLYCERIDES; HUMANS; INOSITOL PHOSPHATES; KCNQ POTASSIUM CHANNELS; MICE; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; SILICONE ELASTOMERS; TRANSFECTION;

EID: 84902603267     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1406728111     Document Type: Article

References (48)

1. Di Marzo V (2008) Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov 7(5):438-455.
2. Di Marzo V, Bisogno T, De Petrocellis L (2000) Endocannabinoids: New targets for drug development. Curr Pharm Des 6(13):1361-1380.
3. Rani Sagar D, Burston JJ, Woodhams SG, Chapman V (2012) Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci 367(1607):3300-3311.
4. Smith PF (2005) Cannabinoids as potential anti-epileptic drugs. Curr Opin Investig Drugs 6(7):680-685.
5. Iannotti FA, et al. (2013) Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats. Prostaglandins Leukot Essent Fatty Acids 89(2-3):127-135.
6. Esposito I, et al. (2008) The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 74(6):1678-1686.
7. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA (2007) Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267(1-2):63-69.
8. Walsh K, Perlman H (1997) Cell cycle exit upon myogenic differentiation. Curr Opin Genet Dev 7(5):597-602. (Pubitemid 27491422)
9. Bijlenga P, et al. (1998) An ether -à-go-go K+ current, Ih-eag, contributes to the hyperpolarization of human fusion-competent myoblasts. J Physiol 512(Pt 2):317-323. (Pubitemid 28486878)
10. Fischer-Lougheed J, et al. (2001) Human myoblast fusion requires expression of functional inward rectifier Kir2.1 channels. J Cell Biol 153(4):677-686.
11. Bijlenga P, et al. (2000) T-type alpha 1H Ca2+ channels are involved in Ca2+ signaling during terminal differentiation (fusion) of human myoblasts. Proc Natl Acad Sci USA 97(13):7627-7632. (Pubitemid 30431514)
12. v7 (KCNQ) channels in myoblast differentiation and proliferation. Biochem Biophys Res Commun 369(4):1094-1097.
13. v7 potassium channels in skeletal muscle proliferation, differentiation, and survival after myotoxic insults. J Pharmacol Exp Ther 332(3):811-820.
14. v7.4 potassium channels. Mol Biol Cell 24(3):274-284.
15. Brown DA, Adams PR (1980) Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 283(5748):673-676. (Pubitemid 10099998)
16. Cruzblanca H, Koh DS, Hille B (1998) Bradykinin inhibits M current via phospholipase C and Ca2+ release from IP3-sensitive Ca2+ stores in rat sympathetic neurons. Proc Natl Acad Sci USA 95(12):7151-7156.
17. Colino A, Halliwell JV (1987) Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin. Nature 328(6125):73-77. (Pubitemid 17103584)
18. Moore SD, Madamba SG, Joëls M, Siggins GR (1988) Somatostatin augments the M-current in hippocampal neurons. Science 239(4837):278-280. (Pubitemid 18061494)
19. Suh BC, Hille B (2005) Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. Curr Opin Neurobiol 15(3):370-378.
20. Schweitzer P (2000) Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons. J Neurosci 20(1):51-58.
21. Lauckner JE, et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105(7):2699-2704. (Pubitemid 351520576)
22. Hanus L, et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98(7):3662-3665. (Pubitemid 32249827)
23. Fezza F, et al. (2002) Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513(2-3):294-298. (Pubitemid 34251281)
24. Hillard CJ, et al. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289(3):1427-1433. (Pubitemid 29246674)
25. Rinaldi-Carmona M, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350(2-3):240-244. (Pubitemid 24268029)
26. Gatley SJ, et al. (1997) Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61(14): PL191-PL197. (Pubitemid 27394368)
27. Huffman JW, et al. (1999) 3-(1́,1́-Dimethylbutyl)-1-deoxy- delta8-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7(12):2905-2914. (Pubitemid 30105863)
28. Ross RA, et al. (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126(3):665-672. (Pubitemid 29087845)
29. Bennett AM, Tonks NK (1997) Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 278(5341):1288-1291. (Pubitemid 27495740)
30. Boczán J, Boros S, Mechler F, Kovács L, Bíró T (2000) Differential expressions of protein kinase C isozymes during proliferation and differentiation of human skeletal muscle cells in vitro. Acta Neuropathol 99(2):96- 104.
31. Wang HS, Brown BS, McKinnon D, Cohen IS (2000) Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol 57(6):1218-1223. (Pubitemid 30354394)
32. Hermann H, et al. (2003) Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 60(3):607-616. (Pubitemid 36459539)
33. Lauckner JE, Hille B, Mackie K (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102(52):19144-19149. (Pubitemid 43049580)
34. De Petrocellis L, et al. (2007) Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Exp Cell Res 313(14): 2993-3004. (Pubitemid 47135571)
35. Marini P, et al. (2009) Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: Interactions with muscarinic and delta-opioid receptors. Biochim Biophys Acta 1793(7):1289-303.
36. Murthy KS, Zhou H, Huang J, Pentyala SN (2004) Activation of PLC-delta1 by Gi/ocoupled receptor agonists. Am J Physiol Cell Physiol 287(6):C1679-C1687. (Pubitemid 39507685)
37. Maccarrone M, et al. (2003) The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermaldifferentiation through CB1 receptordependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278(36):33896-903. (Pubitemid 37553223)
38. Gary-Bobo M, et al. (2006) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69(2):471-478. (Pubitemid 43121944)
39. Ofek O, et al. (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103(3):696-701. (Pubitemid 43153088)
40. Turu G, Hunyady L (2010) Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 44(2):75-85.
41. Berridge MJ (2009) Inositol trisphosphate and calcium signalling mechanisms. Biochim Biophys Acta 1793(6):933-940.
42. Faenza I, et al. (2008) Nuclear phospholipase C beta1 and cellular differentiation. Front Biosci 13:2452-2463. (Pubitemid 351599697)
43. v7 potassium channels. Physiology (Bethesda) 26(5):365-376.
44. Miceli F, et al. (2011) The voltage-sensing domain of K(v)7.2 channels as a molecular target for epilepsy-causing mutations and anticonvulsants. Front Pharmacol 2:2.
45. v7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci 25(43): 9825-9835.
46. Carrasco MA, Jaimovich E, Kemmerling U, Hidalgo C (2004) Signal transduction and gene expression regulated by calcium release from internal stores in excitable cells. Biol Res 37(4):701-712.
47. Matias I, et al. (2008) Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol 286(1-2, Suppl 1): S66-S78.
48. Mulder J, et al. (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134(Pt 4):1041-1060.